Abstract. Eps8 was initially identified as a substrate of the epidermal growth factor receptor. Overexpression of Eps8 leads to increased mitogenic signaling and malignant transformation. However, little is known concerning the importance of Eps8 in human gliomas. In this study, we found that Eps8 was overexpressed in 56.6% of human gliomas (WHO grades III and IV) compared with adjacent normal brain tissues by immunohistochemical analysis. The U251 human glioma cell line stably expressing Eps8 was established by G418 screening, and the ectopic expression of Eps8 enhanced U251 glioma cell growth and survival by cell survival, MTT and liquid colony formation assays. By contrast, the lentiviral expression of Eps8 siRNA in SHG-44 cells resulted in a significant reduction in cellular growth and proliferation. Furthermore, Eps8 modulated the levels of phosphorylated extracellular signal-regulated protein kinase (ERK), phosphorylated serine-threonine protein kinase Akt and β-catenin expression in glioma cell lines and tissues. These results suggest that Eps8 is overexpressed in human gliomas, and affects glioma cell growth possibly by regulating ERK and Akt/β-catenin signaling. Therefore, Eps8 may represent a novel potential target in human glioma therapy.
Introduction
Gliomas are the most common form of primary human brain tumors, and the incidence rate is approximately 40-50% among all brain tumors. Malignant gliomas are associated with a poorly prognosis and survival rate because of their highly invasive behavior, which results in incomplete tumor resection and a major obstacle to any therapeutic remedies including surgery, radiotherapy and chemotherapy (1) . In recent years molecular-targeted therapies are a new strategy for the treatment of gliomas to block cell signaling that governs cell growth, survival and migration (2) . Epidermal growth factor receptor (EGFR) gene amplification and overexpression are a striking feature of high-grade gliomas (3) . EGFR inhibitors were found to promote significant clinical response in a subset of malignant glioma patients (4, 5) .
Eps8 is a substrate of both the receptor and non-receptor tyrosine kinases (6, 7) . Eps8 increased the mitogenic response to EGF and contributes to EGF-dependent cellular tranformation (6, 8, 9) . Eps8, Abi-1 and Sos1 form a tricomplex and induce Rac-specific guanine nucleotide exchange factor (GEF) activity, and enhance Rac-dependent actin remodeling (10) (11) (12) . Further studies showed that the C-terminal effector region of Eps8 binds with F-actin and localizes to main sites of actin remodeling, such as lamellipodia, filopodia and membrane ruffles (10, 11) . Recently, many studies have shown that Eps8 functions in various solid tumors, including squamous cell carcinoma, pancreatic cancer and cervical cancer, as well as colon cancer and pituitary tumors (13) (14) (15) (16) (17) (18) . Moreover, high expression and concomitant tyrosine phosphorylation of Eps8 were detected in tumor cell lines (9) . Eps8 increases cell growth and motility, by the upregulation of FOXM1, FAK, MMP-9, ERK, Akt, cyclins D1, D3 and E, and the down regulation of P53 and p21Waf1/Cip1 in cancer cells (13) (14) (15) 17, 18) . Additionally, the Sp1 inhibitor mithramycin downregulates Eps8 expression and inhibits human epithelial carcinoma cell proliferation and migration, which clearly suggests the Eps8 knockdown may exert an anticancer ability (19) .
Although recent studies imply a critical role for Eps8 in the development of many malignancies, the expression and function of Eps8 in gliomas have not been fully elucidated. In this study, we attempted to investigate the expression of Eps8 in glioma tissues and cell lines, as well as the role of Eps8 in glioma malignancy, including cell proliferation and survival. Overexpression of Eps8 significantly enhanced the growth of the glioma cells, whereas inhibition of Eps8 by a lentiviral RNAi system had an ) and cloned into the lentivirus-based RNAi vector pGCSIL-GFP. A nontargeting stem-loop DNA was also inserted into the pGCSIL-GFP vector as a negative control (NC). Lentiviral particles were prepared as described previously (23) . SHG-44 cells were infected with Eps8-RNAilentivirus or NC-GFP-lentivirus and detected on day 6 by a fluorescence microscope and western blot analysis.
Cell proliferation assays. For cell survival assays, 5,000 cells stably expressing GFP-Eps8 or GFP and parental U251 cells were plated in triplicate in 6-well plates in complete medium containing 400 µg/ml G418. For SHG-44 cells, 5,000 cells expressing Eps8-RNAi-LV or NC-GFP-LV were plated in triplicate in 6-well plates. After 8-10 days, cell numbers were counted with a hemocytometer after trypan blue staining of viable cells. For the cell viability assay, 3,000 cells were seeded in octuplicate in 96-well plates. On days 1, 4, 8 and 10 or days 1, 3, 5 and 8, cells were treated with 1 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenytetrazolium bromide (MTT) at 37˚C for 4 h. Then 100 µl dimethylsulfoxide (DMSO) was added to the medium to dissolve the formazan crystals. The absorbency value at 490 nm in each well was obtained using a spectrophotometer (UV-2102C, Changsha, China). The liquid colony formation was carried out. 1,000 cells were seeded in triplicate in 6-well plates, and cells were grown for 2 weeks in a humidified incubator at 37˚C with 5% CO 2 . Colonies were fixed with methanol, stained with Giemsa (BBI International, Cardiff, UK) and photographed with a digital camera (Olympus, Tokyo, Japan). Only colonies containing over 30 cells were counted.
Statistical analysis. Data are presented as the means ± SD from at least three independent experiments. The significance of difference was assessed using the Student's t-test. Values of p﹤0.05 were considered statistically significant.
Results

Expression of Eps8 in glioma tissues and cell lines.
The expression level of Eps8 was examined in 10 WHO grade III, 43 WHO grade IV gliomas and 7 adjacent normal human brain tissues by immunohistochemical analysis using mouse monoclonal Eps8-specific antibody. We found that Eps8 was completely localized in the cytoplasm (Fig. 1A) . Eps8 expression was detected in 30 (56.6%) of the 53 brain tumors with strong staining (3+), 20 (37.7%) of the 53 gliomas were moderately stained (2+), and 3 (5.7%) were weakly stained or negative for Eps8 expression (+/0), which showed Eps8 was significantly highly expressed in the gliomas (P﹤0.001; Student's t-test). A complete loss of Eps8 expression was observed in normal brain tissues (Fig. 1B) . Therefore, Eps8 expression was markedly increased in the human glioma tissues when compared with expression in the normal brain tissues.
We next analyzed the expression of Eps8 protein in three human glioma cell lines (A172, U251 and SHG-44) and human neuroblastoma cell line SH-SY5Y. Higher expression of Eps8 protein was evident in the SHG-44 cells when compared with that in the A172 and U251 cells. SH-SY5Y cells demonstrated a slight level of Eps8 protein (Fig. 1C) . Thus, the level of Eps8 expression differed in the two glioma cell lines. U251 and SHG-44 cell lines were further selected to overexpress and knockdown Eps8 protein, respectively.
Eps8 overexpression enhances the proliferation of the U251 human glioma cell line. To further investigate the role of Eps8 in human glioma cells, we constructed the pEGFP-C3/Eps8 plasmid and established U251 cell lines stably overexpressing GFP/Eps8 and GFP by G418 screening (Fig. 2A) . The level of Eps8 overexpression was demonstrated by western blotting. As shown in Fig. 2B , U251-GFP and U251-GFP/Eps8 cells were found to express the target proteins at high levels.
We next examined whether Eps8 overexpression in U251 glioma cells promotes cell proliferation. Cells were plated in triplicate in 6-well plates, and the cell number was counted on day 10. We found that the overexpression of Eps8 in U251 cells resulted in an increased cellular growth compared with the controls (Fig. 2C ). Similarly, we tested the cell viability using MTT assay, Eps8 overexpression resulted in a striking increase in the number of viable cells (Fig. 2D) . Furthermore, the liquid colony formation assay demonstrated a great increase in the numbers of colonies of the Eps8-overexpressing U251 cells (Fig. 2E) . Taken together, these data suggest that Eps8 contributes to glioma cell survival and proliferation in vitro.
Eps8 knockdown antagonizes the proliferation of the SHG-44
human glioma cell line. The above results indicate that Eps8 significantly promotes U251 cellular proliferation. To gain further supporting evidence, we knocked down Eps8 expression using shRNA and determined whether shRNA-mediated Eps8 knockdown inhibits the proliferative effects. Four siRNA sequences targeting different regions of Eps8 mRNA were constructed and their abilities to knock down Eps8 expression in transfected HEK293FT cells were demonstrated by western blotting. As shown in Fig. 3 , the four sequences knocked down the Eps8 gene to different levels, especially siRNA1 and siRNA2.
Consequently, siRNA1 and siRNA2 were designed to construct the lentivirus-based RNAi vector pGCSIL-Eps8. Packaging plasmids and pGCSIL-Eps8 were cotransfected into the 293T cells. The fluorescence intensity was markedly increased 4 days after transfection and the transfection efficiency was nearly 90% in the SHG-44 cells (Fig. 4A) . Meanwhile, the expression of Eps8 proteins was detected by western blot analysis. Eps8 shRNA1 and shRNA2 significantly suppressed the expression of Eps8 protein when compared with the negative control shRNA (Fig. 4B) . Given that Eps8 is a critical regulator of glioma cell proliferation, we examined the effect of Eps8 on SHG-44 glioma cell proliferation. As shown in Figs. 4C and D, Eps8 knockdown markedly inhibited the proliferation of SHG-44 cells, whereas control shRNA exhibited no effect. The colony formation assays showed that deletion of Eps8 expression produced a significant decrease in the clonogenicity of SHG-44 cells, while control shRNA produced no effect (Fig. 4E) . These data clearly indicate that Eps8 knockdown reduces glioma cell proliferation.
Eps8 affects the expression of phosphorylated ERK, Akt and β-catenin in glioma cell lines and tissues. Since Eps8 regulates many genes involved in the development of human cancers, we determined to investigate whether Eps8 influences these target genes in glioma cell lines and tissues. As shown in Fig. 5A , Eps8 overexpression had no effect on ERK and Akt protein levels, while it increased the levels of phosphorylated ERK and Akt expression. Moreover, the level of β-catenin was concomitantly enhanced in Eps8-transfected cells. Likely, Eps8 knockdown decreased the expression of phosphorylated ERK, phosphorylated Akt and β-catenin, but not ERK or Akt (Fig. 5B) .
We then analyzed the expression of Eps8 and target genes in normal brain tissues and gliomas. Eps8 had a significantly higher expression in high grade gliomas (WHO III-IV) than in low grade gliomas (WHO I-II) and normal brain tissues. In addition, the expression of Eps8 revealed broadly paralleled expression of target genes in the gliomas and normal brain tissues, particularly phosphorylated ERK and phosphorylated Akt. However, the levels of β-catenin were partially correlated with Eps8 expression in certain samples (Fig. 5C) . Taken together, these data show that Eps8 regulates cell proliferation and survival, at least in part, by affecting phosphorylated ERK and Akt/β-catenin activities. 
Discussion
The human Eps8 family includes Eps8 and three related proteins Eps8L1, Eps8L2, and Eps8L3. Eps8Ls display 27-42% identity to Eps8. However, Eps8L2 and Eps8 display the highest degree of amino acid identity within the family, which explains for the lack of overt phenotype in Eps8 null mice. Only Eps8 is specifically expressed in the brain of the 16.5 dpc mouse embryo among the Eps8 family (24) . In addition, it has also been reported that Eps8 is enriched in the growth cone and filopodia of developing hippocampal neurons (25) . Thus, Eps8 is likely to function in the process of neurodevelopment.
Previous data showed that Eps8 is important in regulating the progression of certain types of human cancers. However, the role of Eps8 in human gliomas has not been previously reported. In the present study, we provide evidence concerning the expression of Eps8 in glioma tissues and cell lines. As assessed by immunohistochemical analysis, Eps8 expression was detectable in the majority of the glioma specimens examined. More importantly, Eps8 protein was significantly higher in 56.6% of high grade (III and IV) glioma tissues compared to normal brain tissues. Accordingly, 3 glioma cell lines were used to demonstrate that the protein level of Eps8 was upregulated in glioma specimens, which was consistent with previous evidence that high expression of Eps8 is noted in tumor cell lines and tissues (9) . Thus, Eps8 expression may clinically designate high grade malignant gliomas.
The evidence presented here also verified the effect of Eps8 on glioma cell proliferation. We established a stable cell line overexpressing Eps8 using U251 cells which have low constitutive expression of Eps8. We used this cell line to investigate the effect of Eps8 over expression on glioma cellular growth in vitro. Eps8 overexpression markedly enhanced cell proliferation. Conversely, we constructed lentivirus-based RNAi vector pGCSIL-Eps8 to knock down Eps8 expression in the SHG-44 cell line, which exhibits high expression of Eps8. Depletion of Eps8 reversed the growth phenotype of Eps8-overexpressing glioma cells. Our data strongly indicate that Eps8 expression is critical for the cell proliferation of malignant gliomas and is possibly involved in malignant progression in human gliomas.
Eps8, Abi-1 and Sos1 are known to form a tricomplex and induce Rac-specific guanine nucleotide exchange factor (GEF) activity, transduce signals from Ras to Rac and enhance Rac-dependent actin remodeling (10) (11) (12) . Additional, Eps8 activates Ras and Raf. Raf then activates MEK, which in turn activates ERK (26) . ERK is known to be a critical regulator that mainly participates in the stimulation of cell proliferation and survival (27) . We demonstrated that Eps8 plays an important role in the growth of glioma cells by regulating the expression of phosphorylated ERK.
β-catenin functions as a core member of canonical Wnt signaling. When Wnt binds to its receptor, transcription factor β-catenin accumulates in the cytoplasm and then trans locates to the nucleus where it subsequently transactivates Wnt pathway downstream targets known to be crucial in cancer develoment (28, 29) . β-catenin is an oncogene in a broad range of human cancers (29, 30) . For example, overexpression of β-catenin contributes to glioma progression (31, 32) . Eps8 was reported to trigger increased proliferation through activation of PI3K via Akt (16, 33) . Moreover, β-catenin can be transactivated via the PI3K/Akt pathway (34, 35) . Therefore, our finding that Eps8 knockdown in glioma cells downregulates the overall level of phosphorylated Akt and β-catenin and vice versa, suggesting that Eps8 may effectively regulate Akt/β-catenin signaling in gliomas.
In summary, this study reveals the biological significance of Eps8 expression in gliomas. We report that Eps8 is highly expressed in malignant gliomas, which correlates with glioma cell proliferation. We found that Eps8 mediates cell proliferation and survival of glioma cells, at least in part, by affecting phosphorylated ERK and Akt/β-catenin activities. These data suggest that Eps8 may be a potential therapeutic target against human gliomas. 
